Septerna (NASDAQ:SEPN) Shares Down 7.6% – Here’s Why

Septerna, Inc. (NASDAQ:SEPN)’s stock price was down 7.6% during mid-day trading on Monday . The stock traded as low as $27.96 and last traded at $27.8950. Approximately 27,361 shares were traded during trading, a decline of 91% from the average daily volume of 308,295 shares. The stock had previously closed at $30.20.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on SEPN shares. Truist Financial upped their price objective on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Septerna in a research report on Wednesday, May 13th. Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $60.00 target price on shares of Septerna in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.13.

Septerna Trading Down 8.0%

The company has a fifty day moving average price of $25.48 and a two-hundred day moving average price of $26.15. The firm has a market capitalization of $1.25 billion, a PE ratio of -34.45 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. As a group, equities research analysts predict that Septerna, Inc. will post -1.57 earnings per share for the current year.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $23,837.58. This represents a 93.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Septerna

Several institutional investors and hedge funds have recently added to or reduced their stakes in SEPN. Woodline Partners LP raised its stake in Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after acquiring an additional 282,585 shares during the last quarter. Rhumbline Advisers raised its stake in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after acquiring an additional 3,323 shares during the last quarter. Geode Capital Management LLC raised its stake in Septerna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after acquiring an additional 78,316 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC purchased a new stake in Septerna during the 2nd quarter valued at approximately $133,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.